These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 14756383)

  • 1. Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects.
    Stass H; Nagelschmitz J; Moeller JG; Delesen H
    Int J Clin Pharmacol Ther; 2004 Jan; 42(1):23-9. PubMed ID: 14756383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers.
    Burkhardt O; Stass H; Thuss U; Borner K; Welte T
    Clin Pharmacokinet; 2005; 44(9):969-76. PubMed ID: 16122283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.
    Stass H; Kubitza D; Möller JG; Delesen H
    Br J Clin Pharmacol; 2005 May; 59(5):536-41. PubMed ID: 15842551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery.
    De Smet J; Colin P; De Paepe P; Ruige J; Batens H; Van Nieuwenhove Y; Vogelaers D; Blot S; Van Bocxlaer J; Van Bortel LM; Boussery K
    J Antimicrob Chemother; 2012 Jan; 67(1):226-9. PubMed ID: 21987240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
    Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
    Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration.
    Stass H; Kubitza D; Schühly U
    Clin Pharmacokinet; 2001; 40 Suppl 1():1-9. PubMed ID: 11352436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers.
    Barone JA; Moskovitz BL; Guarnieri J; Hassell AE; Colaizzi JL; Bierman RH; Jessen L
    Pharmacotherapy; 1998; 18(2):295-301. PubMed ID: 9545149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.
    Stass H; Kubitza D
    J Antimicrob Chemother; 1999 May; 43 Suppl B():83-90. PubMed ID: 10382880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction.
    Stass H; Bührmann S; Mitchell A; Kubitza D; Möller JG; Kribben A; Wenzel RR; Schäfers RF
    Br J Clin Pharmacol; 2007 Dec; 64(6):745-9. PubMed ID: 17555469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.
    Breilh D; Jougon J; Djabarouti S; Gordien JB; Xuereb F; Velly JF; Arvis P; Landreau V; Saux MC
    J Chemother; 2003 Dec; 15(6):558-62. PubMed ID: 14998080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers.
    Kanjanawart S; Gaysonsiri D; Phunikom K; Simasathiansopon S; Tangsucharit P; Vannaprasaht S; Kaewkamson T; Tassaneeyakul W
    Int J Clin Pharmacol Ther; 2013 Mar; 51(3):249-54. PubMed ID: 23357835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline.
    Stass H; Kubitza D
    Clin Pharmacokinet; 2001; 40 Suppl 1():63-70. PubMed ID: 11352444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
    Stass H; Böttcher MF; Ochmann K
    Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
    Dooley K; Flexner C; Hackman J; Peloquin CA; Nuermberger E; Chaisson RE; Dorman SE
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4037-42. PubMed ID: 18765687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction.
    Stass H; Kubitza D; Halabi A; Delesen H
    Br J Clin Pharmacol; 2002 Mar; 53(3):232-7. PubMed ID: 11874385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
    J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
    Weiner M; Burman W; Luo CC; Peloquin CA; Engle M; Goldberg S; Agarwal V; Vernon A
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2861-6. PubMed ID: 17517835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.
    Sullivan JT; Woodruff M; Lettieri J; Agarwal V; Krol GJ; Leese PT; Watson S; Heller AH
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2793-7. PubMed ID: 10543767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study.
    Stass H; Delesen H; Kubitza D; Mai I; Bauer S; Roots I
    Clin Drug Investig; 2010; 30(5):279-87. PubMed ID: 20384384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.